Clinical Significance of Determination Serum CA19-9 in Patients with Chronic Liver Disease

To study the clinical diagnostic value of serum carbohydrate antigen 19-9 (CA19-9) in patients with liver carcinoma and cirrhosis. Methods: Patients with liver carcinoma 42. 56 cirrhosis, 36 chronic hepatitis and 40 healthy controls were detected the levels of serum CA19-9 by using IRMA methods. Results: The levels of serum CA19-9 in liver cancer group was 232. 4±113. 5U/L, cirrhosis group was 82. 6±34. 3U/L, chronic hepatitis was 10. 2±3. 6U/ L, and the healthy controls group was 9. 8±4. 3U/L. Amount of it liver carcinoma group was singnificantly highter than that in cirrhosis group, Chronic hepatitis group and normal controls group (P0. 01). In cirrhosis group it was also singnificntly highter than in chronic heaptitis group and healthy controls group (P0.01). But there was no difference between chronic hepatitis group and normal controls group (P0. 05). When 29U/L was taken as the cutoff value the positive rate in liver cancer group was 73. 8 (31/42), cirrhosis group was 39. 3% (22/36), chronic hepatitis group was 5. 5% (2/36),normal controls group was 0% (0/40). Liver carcinoma group was significantly highter than that in cirrhosis group, chronic hepatitis group and normal controls (P0.001). In cirrhosis group it was also singnificantly highter than that in chronic heaptitis group and normal controls group (P0. 01). But there was no difference between chronic hepatitis group and normal controls group (P0. 05). We also found there was a positive correlation between serum CA19-9 and γ-GT(r = 0. 84,P0. 01). Conclusion:Serum CA19-9 may help for the diagnosis of patients with liver carcinoma and cirrhosis, and can be used as an adjuvant indices to diagnose liver carcinoma and cirrhosis.